Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia

Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis

(2012) E Kerr et al.   CELL DEATH AND DIFFERENTIATION

A Systems Biology Approach Identifies SART1 as a Novel Determinant of Both 5-Fluorouracil and SN38 Drug Resistance in Colorectal Cancer

(2011) W. L. Allen et al.   MOLECULAR CANCER THERAPEUTICS

Targeting c-FLIP in cancer

(2010) Sarah Shirley et al.   CANCER LETTERS

Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer

(2010) D. P. McLornan et al.   CLINICAL CANCER RESEARCH

Chemical phylogenetics of histone deacetylases

(2010) James E Bradner et al.   Nature Chemical Biology

The leukemic stem cell niche: current concepts and therapeutic opportunities

(2009) S. W. Lane et al.   BLOOD

High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide

(2009) Alessia Petronelli et al.   CANCER LETTERS

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing

(2009) T R Wilson et al.   CELL DEATH AND DIFFERENTIATION

The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation

(2009) Daniela Carlisi et al.   EUROPEAN JOURNAL OF CANCER

A phase 2 study of vorinostat in acute myeloid leukemia

(2009) E. W. Schaefer et al.   HAEMATOLOGICA

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis

(2008) Patricia Balsas et al.   BIOCHEMICAL PHARMACOLOGY

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

(2008) G. Garcia-Manero et al.   BLOOD

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

(2008) N. L. Steele et al.   CLINICAL CANCER RESEARCH

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

(2008) A. J. Frew et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts

(2007) Lalji K. Gediya et al.   BIOORGANIC & MEDICINAL CHEMISTRY